Thus, considering our results and those of others, although the evidence remains limited, a suitable drug design, such as C70PLY4, targeting TLR4 activity might provide an opportunity to effectively treat the majority of chronic inflammatory and autoimmune diseases in the future. This evidence concerns the gene TLR4 and autoimmune disease.